An Insight into Molecular Targets of Breast Cancer Brain Metastasis.
Mohammed KaleemMahmood Hassan DalhatLubna AzmiTurky Omar AsarWasim AhmadMaimonah AlghanmiAmal AlmostadiTorki Al ZughaibiShams TabrezPublished in: International journal of molecular sciences (2022)
Brain metastasis is one of the major reasons of death in breast cancer (BC) patients, significantly affecting the quality of life, physical activity, and interdependence on several individuals. There is no clear evidence in scientific literature that depicts an exact mechanism relating to brain metastasis in BC patients. The tendency to develop breast cancer brain metastases (BCBMs) differs by the BC subtype, varying from almost half with triple-negative breast cancer (TNBC) (HER2 - ER - PR - ), one-third with HER2 + (human epidermal growth factor receptor 2-positive, and around one-tenth with luminal subclass (ER + (estrogen positive) or PR + (progesterone positive)) breast cancer. This review focuses on the molecular pathways as possible therapeutic targets of BCBMs and their potent drugs under different stages of clinical trial. In view of increased numbers of clinical trials and systemic studies, the scientific community is hopeful of unraveling the underlying mechanisms of BCBMs that will help in designing an effective treatment regimen with multiple molecular targets.
Keyphrases
- clinical trial
- end stage renal disease
- epidermal growth factor receptor
- physical activity
- newly diagnosed
- ejection fraction
- chronic kidney disease
- positive breast cancer
- white matter
- small cell lung cancer
- prognostic factors
- estrogen receptor
- healthcare
- peritoneal dialysis
- resting state
- endothelial cells
- single molecule
- patient reported outcomes
- blood brain barrier
- functional connectivity
- molecular dynamics
- cerebral ischemia
- smoking cessation
- induced pluripotent stem cells
- placebo controlled